Abstract 483P
Background
Treatment with an EGFR TKI is the standard of care for patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC, based on findings from randomized controlled trials, but acquired resistance is inevitable. A phase IIIb study (NCT01853826) was conducted to assess outcomes with afatinib in a broad EGFRm+ NSCLC patient population, similar to real-world practice. Here we report results from a sub-study of the trial, to assess the relationship between afatinib efficacy and the presence of biomarkers associated with resistance to EGFR TKIs.
Methods
EGFR TKI-naïve pts with locally advanced/metastatic EGFRm+ NSCLC and ECOG PS 0–2 received afatinib starting at 40 mg/day. Tumor biopsies were performed prior to study entry; baseline T790M status (presence vs absence), and total BIM, BIMEL and mTOR mRNA expression (high vs low, according to median values) were analyzed for patients who consented to sub-study participation. Exploratory efficacy analyses were conducted. Time to symptomatic progression (TTSP) and progression-free survival (PFS) were calculated using the Kaplan–Meier method.
Results
A total of 113 pts were included in this sub-study (data cut-off 21 June 2018). Baseline characteristics, n (%): white race, 112 (99); female, 70 (62); 1st/2nd/≥3rd-line therapy, 94/16/3 (83/14/3); ECOG PS 0/1, 106 (94); brain metastases, 16 (14); common/uncommon mutations, 105/8 (93/7). Median time on treatment was 581 days. Objective response/disease control rates were 58%/95%. Median (95% CI) TTSP was 20.6 months (18.9–24.9) and PFS was 19.8 months (16.1–23.5). TTSP and PFS by biomarker status at baseline are reported in the table.
Table: 483P
TTSP | PFS | |||
---|---|---|---|---|
Median (95% CI) | HR (95% CI) | Median (95% CI) | HR (95% CI) | |
T790M* | ||||
Present (n = 51) Absent (n = 60) | 19.5 (14.9–25.1) 21.4 (17.7–26.3) | 1.0 (0.67–1.60) | 18.8 (14.1–24.0) 21.4 (15.9–26.1) | 1.1 (0.7–1.7) |
BIM total mRNA expression† | ||||
High (n = 35) Low (n = 35) | 23.7 (14.7–37.1) 25.7 (19.3–35.8) | 1.2 (0.7–2.1) | 21.8 (14.1–28.5) 26.0 (18.9–35.5) | 1.2 (0.7–2.1) |
BIMEL mRNA expression‡ | ||||
High (n = 22) Low (n = 21) | 19.1 (11.9–24.8) 24.9 (14.8–42.2) | 1.3 (0.6–2.7) | 18.8 (11.6–23.5) 25.2 (16.1–38.6) | 1.4 (0.7–2.9) |
mTOR mRNA expression§ | ||||
High (n = 39) Low (n = 37) | 22.3 (14.8–29.5) 26.1 (19.1–35.8) | 1.0 (0.6–1.7) | 21.8 (14.3–29.5) 23.1 (14.5–35.5) | 1.0 (0.6–1.8) |
Non-evaluable or missing: *n=2; †n = 43; ‡n = 36; §n = 37.
Conclusions
In this broad population of EGFR TKI-naïve pts with EGFRm+ NSCLC who were treated with afatinib, biomarker analysis indicated no notable differences in efficacy outcomes by baseline T790M status (presence vs absence), or baseline mRNA expression of BIM, BIMEL or mTOR (high vs low).
Clinical trial identification
NCT01853826.
Editorial acknowledgement
Laura Winton of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
M. Hochmair: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme, ; Advisory / Consultancy: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Takeda; Speaker Bureau / Expert testimony: Pfizer. R. Ramlau: Advisory / Consultancy: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. J. Skrickova: Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche. P. Bidoli: Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: BMS ; Advisory / Consultancy: Boehringer Ingelheim. L. Clementi: Full / Part-time employment: Boehringer Ingelheim. A. Cseh: Full / Part-time employment: Boehringer Ingelheim. F. De Marinis: Honoraria (self): Roche; Honoraria (self): AstraZeneca; Advisory / Consultancy: Takeda; Research grant / Funding (institution): Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract
249P - Accuracy of endometrial biopsy by Pipelle: A systematic review and meta-analysis
Presenter: Jinhai Gou
Session: Poster display session
Resources:
Abstract
250P - Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities
Presenter: Gonçalo Nogueira da Costa
Session: Poster display session
Resources:
Abstract
251P - A prognostic index model for predicting long-term recurrence of uterine leiomyoma after initial myomectomy in women aged 18-44 years
Presenter: Xiu Ming
Session: Poster display session
Resources:
Abstract
252P - Uterine sarcomas in Qatar: Clinico-pathological characteristics and treatment outcome
Presenter: Ashraf Fadlelseid
Session: Poster display session
Resources:
Abstract
253P - Anti-PD-1-induced reinvigoration of tumour-infiltrating CD8+ T cells in epithelial ovarian cancer patients is correlated with T cell factor-1
Presenter: Junsik Park
Session: Poster display session
Resources:
Abstract
254P - Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)
Presenter: Diar Aziz
Session: Poster display session
Resources:
Abstract
255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data
Presenter: Huining Jing
Session: Poster display session
Resources:
Abstract
256P - Lnc-AL445665.1-4 may be involved in the development of multiple uterine leiomyoma through interacting with miR-146b-5p
Presenter: E Yang
Session: Poster display session
Resources:
Abstract
257P - Treatment results of low risk gestational trophoblastic neoplasia (GTN) from a tertiary hospital, Chennai, India
Presenter: Rakesh M. P
Session: Poster display session
Resources:
Abstract